GLP‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
Diabetes Obesity and Metabolism,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 10, 2025
Abstract
Aims
The
associations
of
glucagon‐like
peptide‐1
receptor
agonists
(GLP‐1RAs)
and
outcomes
among
patients
with
obesity
according
to
the
presence
cardiovascular
risk
factors
(metabolically
healthy
(MHO)
or
metabolically
unhealthy
(MUHO))
remain
unclear.
We
examined
GLP‐1RAs
mortality
adverse
events
in
MHO
MUHO.
Methods
TriNetX
network
was
utilized
select
a
cohort
MUHO,
use
non‐use
propensity
score
matching
(1:1).
Cardiovascular
were
identified
during
follow‐up.
Results
A
total
2
983
151
(512
434
470
717
MUHO)
included
study.
Among
these,
416
713
(13.9%)
GLP‐1RA
users.
After
matching,
MUHO
associated
significantly
lower
(HR
0.580
[95%
CI,
0.566–0.595]),
ischemic
stroke
0.921
[0.890–0.953]),
AF
0.913
[0.888–0.938])
hospitalization
for
HF
0.925
[0.900–0.949])
follow‐up
compared
GLP‐1RA.
Patients
had
markedly
clinical
than
those
trend
towards
seen
MHO.
There
no
statistical
interaction
patients.
Conclusions
rates
Similar
but
non‐statistically
significant
trends
Язык: Английский
Consensus Guidelines for the Diagnosis and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Adult Asian Indians with Type 2 Diabetes
Diabetes & Metabolic Syndrome Clinical Research & Reviews,
Год журнала:
2025,
Номер
19(3), С. 103209 - 103209
Опубликована: Март 1, 2025
Язык: Английский
Targeting Diabetic Atherosclerosis: The Role of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Nonsteroidal Mineralocorticoid Receptor Antagonists in Vascular Protection and Disease Modulation
Biomedicines,
Год журнала:
2025,
Номер
13(3), С. 728 - 728
Опубликована: Март 17, 2025
Atherosclerosis
is
a
closely
related
complication
of
diabetes
mellitus
(DM),
driven
by
endothelial
dysfunction,
inflammation,
and
oxidative
stress.
The
progression
atherosclerosis
accelerated
hyperglycemia,
insulin
resistance,
hyperlipidemia.
Novel
antidiabetic
agents,
SGLT2
inhibitors,
GLP-1
agonists
improve
glycemic
control
offer
cardiovascular
protection,
reducing
the
risk
major
adverse
events
(MACEs)
heart
failure
hospitalization.
These
along
with
nonsteroidal
mineralocorticoid
receptor
antagonists
(nsMRAs),
promise
to
mitigate
metabolic
disorders
their
impact
on
function,
stress,
inflammation.
This
review
explores
potential
molecular
mechanisms
through
which
these
drugs
may
prevent
development
disease
(CVD),
supported
summary
preclinical
clinical
evidence.
Язык: Английский
From Prescription to Predicament: A Case of Semaglutide-Induced Discoid Lupus Erythematosus in an Adult Male Patient
Cureus,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 3, 2025
Язык: Английский
Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta‐Analysis of Direct Comparative Studies
Endocrinology Diabetes & Metabolism,
Год журнала:
2025,
Номер
8(3)
Опубликована: Апрель 4, 2025
ABSTRACT
Introduction
Glucagon‐like
peptide‐1
receptor
agonists
(GLP‐1RAs)
have
emerged
as
an
efficacious
treatment
for
type
2
diabetes
mellitus
(T2DM)
and
demonstrated
substantial
weight
loss
effects.
This
systematic
review
compares
two
prevalent
GLP‐1RAs,
tirzepatide
semaglutide,
with
their
effects
rates
of
adverse
events
(AEs).
Methods
Following
the
Preferred
Reporting
Items
Systematic
Reviews
Meta‐Analyses
(PRISMA),
a
search
was
performed
in
PubMed,
Embase
Cochrane
Library
direct
comparative
studies
between
semaglutide.
A
meta‐analysis
conducted
via
random‐effects
model
to
analyse
differences
outcomes
study
cohorts.
Results
Four
studies,
28,827
patients
(14,870
tirzepatide/13,928
semaglutide),
mean
age
55.7
years
(52.0
63.7)
follow‐up
35.9
weeks
(23.6
44.6),
were
included
this
study.
Mean
change
across
four
semaglutide
−11.4%
(−15.3%
−8.27%)
−7.3%
(−8.3%
−6.08%),
respectively.
The
supports
these
findings
difference
−4.84
kg
(95%
CI:
−6.21
−3.47),
favouring
tirzepatide.
most
common
AEs
minor
moderate‐severity
gastrointestinal
(GI)
AEs.
Conclusion
Current
literature
demonstrating
higher
impact
on
than
both
high
minimal‐
Further
research
head‐to‐head
trials
will
better
elucidate
safety
profiles.
Язык: Английский
Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders
Journal of Neurology Neurosurgery & Psychiatry,
Год журнала:
2025,
Номер
unknown, С. jnnp - 335593
Опубликована: Апрель 10, 2025
Disease-modifying
treatments
for
major
neurocognitive
disorders,
including
Alzheimer’s
disease,
Parkinson’s
disease
and
other
cognitive
deficits,
are
among
the
main
unmet
needs
in
modern
medicine.
Glucagon-like
peptide-1
receptor
agonists
(GLP-1RAs),
currently
licensed
treatment
of
type
2
diabetes
mellitus
obesity,
offer
a
novel,
multilayered
mechanism
intervention
neurodegeneration
through
intermediate,
aetiology-agnostic
pathways,
likely
involving
metabolic,
inflammatory
several
relevant
neurobiological
processes.
In
vitro
animal
studies
have
revealed
promising
signals
neuroprotection,
with
preliminary
supportive
evidence
emerging
from
recent
pharmacoepidemiological
investigations
clinical
trials.
this
article,
we
comprehensively
review
that
investigate
impact
GLP-1RAs
on
various
aetiologies
impairment
dementia
syndromes.
Focusing
human
studies,
highlight
how
brain
energy
homeostasis,
neurogenesis,
synaptic
functioning,
neuroinflammation
cellular
stress
responses,
pathological
protein
aggregates,
proteostasis,
cerebrovascular
system
blood-brain
barrier
dynamics
may
underlie
GLP-1RA
putative
neuroprotective
effects.
We
then
report
appraise
observational
investigations,
trials
pooled
analyses.
Finally,
discuss
current
challenges
perspectives
ahead
research
implementation
care
people
their
individual
penetrance
potential,
need
response
biomarkers
stage-based
indications,
possible
non-specific
effects
health,
profile
terms
adverse
events
unwanted
effects,
lack
long-term
data
efficacy
safety,
issues
surrounding
cost
availability
treatment.
Язык: Английский